(VIANEWS) – LNA SANTE (LNA.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| LNA SANTE (LNA.PA) | €20.45 | 2.37% | 7.98% |
| BIOMERIEUX (BIM.PA) | €102.25 | 0.89% | 8.73% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. LNA SANTE (LNA.PA)
2.37% Forward Dividend Yield and 7.98% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 8.97. Meaning, the purchaser of the share is investing €8.97 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.98%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, LNA SANTE’s stock is considered to be oversold (<=20).
Moving Average
LNA SANTE’s value is way below its 50-day moving average of €24.47 and under its 200-day moving average of €21.44.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jul 8, 2024, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 2.37%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.1%, now sitting on 736.08M for the twelve trailing months.
More news about LNA SANTE.
2. BIOMERIEUX (BIM.PA)
0.89% Forward Dividend Yield and 8.73% Return On Equity
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Earnings Per Share
As for profitability, BIOMERIEUX has a trailing twelve months EPS of €3.01.
PE Ratio
BIOMERIEUX has a trailing twelve months price to earnings ratio of 33.97. Meaning, the purchaser of the share is investing €33.97 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.73%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 1.4%, now sitting on 3.67B for the twelve trailing months.
More news about BIOMERIEUX.
